RDHL NASDAQ
RedHill Biopharma Ltd.
1W: +0.0%
1M: -32.5%
3M: -36.7%
YTD: -51.5%
1Y: -80.2%
3Y: -96.8%
5Y: -100.0%
$0.50
+0.02 (+4.17%)
Weekly Expected Move ±10.1%
$0
$0
$0
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$9M
+73.8% ▲
Capital Expenditures
$9K
+18.2% ▲
5Y CAGR: -46.4%
Free Cash Flow
-$9M
+73.8% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$952K
+93.4% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$76M | -$98M | -$72M | $24M | -$8M |
| Depreciation & Amort. | $9M | $18M | $8M | $2M | $619K |
| Stock-Based Comp. | $4M | $10M | $6M | $2M | $665K |
| Change in Working Capital | $8M | -$1M | $8M | -$16M | $2M |
| Other Non-Cash Items | $6M | $5M | $21M | -$48M | -$4M |
| Operating Cash Flow | -$49M | -$65M | -$29M | -$36M | -$9M |
| — Investing Activities — | |||||
| Capital Expenditures | -$54M | -$115K | -$198K | -$11K | -$9K |
| Acquisitions (Net) | $0 | $8M | $0 | $0 | $0 |
| Investment Purchases | $0 | -$8M | $0 | $0 | $0 |
| Investment Sales | $18M | $475K | $8M | $15K | $0 |
| Other Investing | $0 | -$8M | $0 | $0 | $0 |
| Investing Cash Flow | -$36M | -$8M | $8M | $4K | -$9K |
| — Financing Activities — | |||||
| Net Debt Issuance | $76M | -$2M | -$1M | -$1M | -$636K |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$16M | -$3M | -$11M | $9M | $790K |
| Financing Cash Flow | $84M | $73M | $11M | $21M | $8M |
| Net Change in Cash | $272K | $179K | -$10M | -$14M | -$952K |
| Cash End of Period | $29M | $29M | $20M | $6M | $5M |
| Free Cash Flow | -$102M | -$65M | -$29M | -$36M | -$9M |